BrightSpring Health Services’ third quarter results were shaped by strength in its specialty pharmacy and infusion businesses, even as the market reacted negatively to the report. Management pointed to robust script growth—particularly in specialty, where scripts rose over 40%—and highlighted positive contributions from recent limited distribution drug launches. CEO Jon Rousseau noted, “We ended Q3 with 144 limited distribution drugs, including five launches in the quarter,” attributing performance to both commercial execution and operational discipline in expense management. However, headwinds in the Home & Community Pharmacy segment from a divested customer and delayed flu season also influenced the period, leading management to proactively adjust the customer mix for profitability.
Is now the time to buy BTSG? Find out in our full research report (it’s free for active Edge members).
BrightSpring Health Services (BTSG) Q3 CY2025 Highlights:
- Revenue: $3.33 billion vs analyst estimates of $3.17 billion (14.7% year-on-year growth, 5.3% beat)
- Adjusted EPS: $0.30 vs analyst estimates of $0.26 (13.9% beat)
- Adjusted EBITDA: $160.4 million vs analyst estimates of $156.3 million (4.8% margin, 2.6% beat)
- The company lifted its revenue guidance for the full year to $12.65 billion at the midpoint from $12.4 billion, a 2% increase
- EBITDA guidance for the full year is $610 million at the midpoint, in line with analyst expectations
- Operating Margin: 2.6%, up from 1% in the same quarter last year
- Market Capitalization: $6.93 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From BrightSpring Health Services’s Q3 Earnings Call
- Albert Rice (UBS) asked about the pacing and sustainability of new limited distribution drug launches. CEO Jon Rousseau responded that the pipeline remains robust, with no major acceleration but continued strong activity expected over the next 12 to 18 months.
- David Larsen (BTIG) inquired about margin drivers for the Amedisys acquisition and sustainability of EBITDA per script growth. CFO Jennifer Phipps highlighted the mix shift to higher-margin specialty scripts and ongoing efficiency efforts as key contributors.
- Charles Rhyee (TD Cowen) questioned the impact of competitor bankruptcies and opportunities to expand market share. Rousseau indicated minimal material impact, emphasizing BrightSpring’s focus on targeted end markets and enhanced customer screening.
- Kieran Ryan (Deutsche Bank) sought clarity on pharmacy segment guidance and potential slowdowns in specialty and infusion. Phipps answered that strong growth is expected to continue in these areas, with no signs of deceleration into the next quarter.
- Joanna Gajuk (Bank of America) asked about high-level tailwinds and headwinds entering next year. Rousseau cited infusion and specialty as major tailwinds, and pointed to automation and operational investments as key ongoing priorities.
Catalysts in Upcoming Quarters
In the coming quarters, our team will watch (1) the pace and successful commercialization of new limited distribution drugs in the specialty pipeline, (2) realization of operational efficiencies and automation-driven margin gains across pharmacy and provider segments, and (3) integration progress and initial financial contribution from the Amedisys and LHC acquisitions. Additionally, we will monitor regulatory developments and reimbursement trends that could affect segment profitability.
BrightSpring Health Services currently trades at $34.08, in line with $33.99 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free for active Edge members).
Our Favorite Stocks Right Now
Fresh US-China trade tensions just tanked stocks—but strong bank earnings are fueling a sharp rebound. Don’t miss the bounce.
Don’t let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
